anti mouse cd22  (Bio X Cell)

Journal: Molecular Therapy Oncology

Article Title: A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity

doi: 10.1016/j.omton.2026.201127

Figure Lengend Snippet: MV-Blina therapy significantly prolongs the survival of ALL bearing mice (A) Treatment scheme. Two PDX models were established in NSG mice by i.v. injection to induce ALL. At a leukemic load of approximately 35%, mice received treatment i.v. with MV (2.5 × 10 5 TCID 50 /g) or control. Two days after infection, mice were injected with healthy human PBMCs. (B) Superior survival of PDX #2 with MV-Blina compared to MV-Edm. PDX #1 and #2 were treated either with MV-Blina and PBMC ( n = 10) or MV-Edm and PBMC ( n = 10) or control with PBMC only ( n = 10) and observed for a maximum of 70 days. (C) MV-Blina treatment decreases leukemic load. Leukemic blasts (msCD45 − huCD19 + huCD45 dim ) and human PBMC (msCD45 − huCD19 + huCD45 bright ) in peripheral blood were monitored by flow cytometry at the indicated time points. (D) Marked reduction of spleen weight in PDX upon MV-Blina treatment. At the time of death, a complete necropsy was performed, and spleen weight was determined. (E) Significant reduction of leukemic blasts by MV-Blina in ALL compartments. At the time of death, leukemic blasts (msCD45 − huCD19 + huCD45 dim ) were detected by flow cytometry in bone marrow, spleen, and meninges. Replication of secBlina was detected by qRT-PCR and calculated by the 2 −ΔΔCt method, displaying the fold change relative to huActin and huGAPDH. (F) MV-Blina reduces leukemic blasts in the spleen by decreasing proliferation and increasing apoptosis. Spleens of untreated mice at therapy start (d0, n = 4) and treated mice (MV-Blina and PBMC, n = 10; MV-Edm and PBMC, n = 9; PBMC-only control, n = 9) were formalin-fixed, paraffin-embedded, and subsequently stained for H&E, CD22, Ki67, or cleaved Caspase-3 (CC3). Positive area was determined using ImageJ. Scale bars 50 μm. Statistical analysis was performed using Mantel-Cox log rank test (B), one-way ANOVA with Tukey’s multiple comparisons test (C-F). ns, not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; and ∗∗∗∗, p < 0.0001.

Article Snippet: Immunohistochemistry for CD22 was performed using a mouse anti-human CD22 antibody (clone OTI1F2, 1:75, TA506404, Origene, Rockville, MD), for Ki67 using a mouse anti-human Ki67 antibody (clone MIB-1, 1:150, M7240, Dako, Waldbronn, Germany) and for cleaved caspase-3 (CC3) using a rabbit-anti human active caspase-3 antibody (1:200, ab13847, Abcam, Cambridge, UK).

Techniques: Injection, Control, Infection, Flow Cytometry, Quantitative RT-PCR, Formalin-fixed Paraffin-Embedded, Staining

Journal: Journal of neuroinflammation

Article Title: CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

doi: 10.1186/s12974-024-03305-2

Figure Lengend Snippet: Fig. 1 Expression profile of CD22 in circulating immune cell subsets from patients with NMOSD and controls. A Single-cell sequencing analysis of im mune cells from human peripheral blood samples from patients with NMOSD and healthy controls (total: 90,381 cells from 5 NMOSD patients and 5 controls; control: 43,985 cells; NMOSD: 46,396 cells). B, C CD22 expression profiles of B cells B and B-cell subsets C from patients with NMOSD and healthy controls; n = 5 per group. D CD22 expression profiles across various immune cell subsets in patients with NMOSD and healthy controls at the indi vidual patient level; n = 5 per group. E Gating strategy for human circulating immune cell subsets, including neutrophils (CD45+CD3−CD16+), monocytes (CD45+CD16−CD14+), B cells (CD45+CD3−CD19+), CD4+ T cells (CD45+CD3−CD4+), CD8+ T cells (CD45+CD3−CD8+) and NK cells (CD45+CD3−CD56+). F Summarized bar graph showing CD22 expression in monocytes, neutrophils, B cells, CD4+ T cells, CD8+ T cells and NK cells; n = 6 per group. G Visualization of circulating exosomes from patients with NMOSD and controls. H Flow cytometry gating strategy and bar graph showing microglia-derived exosomes (CD22+TMEM119+); n = 8 per group. The data are presented as the mean ± SEM. **p < 0.01

Article Snippet: An anti-CD22 monoclonal antibody (clone ID: CY34.1; BioXcell, West Lebanon, NH) was given to NMOSD mice via intrastriatal injection at a dose of 100 μg/mouse to deplete CD22-expressing cells [24].

Techniques: Expressing, Sequencing, Control, Flow Cytometry, Derivative Assay

Journal: Journal of neuroinflammation

Article Title: CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

doi: 10.1186/s12974-024-03305-2

Figure Lengend Snippet: Fig. 2 CD22 expression profile in microglia and leukocytes from NMOSD mice. A Flow cytometry gating strategy for microglia (CD45+CD11bint), monocytes (CD45highCD11b+Ly6C+), neutrophils (CD45highCD11b+Ly6G+), B cells (CD45highCD3−CD19+), CD4+ T cells (CD45highCD3+CD4+), CD8+ T cells (CD45highCD3+CD8+) and NK cells (CD45highCD3−NK1.1+). B Histograms showing CD22-expressing cell subsets in sham and NMOSD mice. C, D Bar graphs showing the percentage of each cell type expressing CD22 in brain and spleen tissues from NMOSD mice; n = 8 per group. The data are presented as the mean ± SEM. *p < 0.05, **p < 0.01

Article Snippet: An anti-CD22 monoclonal antibody (clone ID: CY34.1; BioXcell, West Lebanon, NH) was given to NMOSD mice via intrastriatal injection at a dose of 100 μg/mouse to deplete CD22-expressing cells [24].

Techniques: Expressing, Flow Cytometry

Journal: Journal of neuroinflammation

Article Title: CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

doi: 10.1186/s12974-024-03305-2

Figure Lengend Snippet: Fig. 3 CD22 blockade exacerbates NMOSD pathology in mice. A T2WI scans revealed demyelinating lesions in the indicated groups of NMOSD mice. The lesion areas are marked with red lines. Scale bar: 2 mm. B Bar graphs depicting the volume of demyelinating lesions in the indicated groups of NMOSD mice; n = 10 per group. C Immunostaining of the indicated markers (GFAP, AQP4, or MBP) in brain tissue sections from NMOSD mice receiving the anti- CD22 mAb or IgG control on day 3 after NMOSD induction. The white lines indicate areas with loss of AQP4, GFAP or MBP. Scale bar: 3,000 μm (left), 100 μm (right). D Bar graphs illustrating demyelination in NMOSD mice receiving anti-CD22 mAb or IgG control; n = 10 per group. The data are expressed as the mean ± SEM. ** p < 0.01

Article Snippet: An anti-CD22 monoclonal antibody (clone ID: CY34.1; BioXcell, West Lebanon, NH) was given to NMOSD mice via intrastriatal injection at a dose of 100 μg/mouse to deplete CD22-expressing cells [24].

Techniques: Immunostaining, Control

Journal: Journal of neuroinflammation

Article Title: CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

doi: 10.1186/s12974-024-03305-2

Figure Lengend Snippet: Fig. 4 CD22 blockade augments the inflammatory activity of microglia in NMOSD mice. A Flow cytometry gating strategy for inflammatory markers (CD86, IL-1β and TNF-α) and immune regulatory markers (CD206, IL-10 and TGF-β) in microglia. B Bar graph showing the effects of CD22 blockade on the counts of microglia, brain-infiltrating monocytes, neutrophils, B cells, CD4+ T cells and CD8+ T cells in NMOSD mice; n = 10 per group. C Flow cytometry results showing the effects of CD22 blockade on the expression of inflammatory markers (CD86, IL-1β and TNF-α) and immunoregulatory markers (CD206, IL-10 and TGF-β) in microglia from NMOSD mice; n = 6 per group. D Immunostaining showing Iba1+ cells in the indicated groups. The white lines delineate the areas with an accumulation of Iba1+ cells. Scale bar: 100 μm. E Bar graph showing that CD22 blockade enhanced the accumulation of Iba1+ cells. n = 10 per group. F, G Skeletal analysis showing that the lengths of microglial processes were reduced on day 3 in mice treated with the anti-CD22 mAb; n = 6 per group. H Sholl analysis summarizing the results of microglial processes in NMOSD mice receiving the anti-CD22 mAb or IgG control. The data are presented as the mean ± SEM. *p < 0.05, **p < 0.01

Article Snippet: An anti-CD22 monoclonal antibody (clone ID: CY34.1; BioXcell, West Lebanon, NH) was given to NMOSD mice via intrastriatal injection at a dose of 100 μg/mouse to deplete CD22-expressing cells [24].

Techniques: Activity Assay, Flow Cytometry, Expressing, Immunostaining, Control

Journal: Journal of neuroinflammation

Article Title: CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

doi: 10.1186/s12974-024-03305-2

Figure Lengend Snippet: Fig. 5 Microglia contribute to exacerbated NMOSD pathology in mice receiving anti-CD22 mAb. A Flow chart depicting drug administration and the indicated assessment. On day 14 after microglial depletion via PLX5622, wild-type mice received intrastriatal injections of anti-CD22 mAb after NMOSD induction. B Assessment of microglia following PLX5622 administration; n = 7 per group. C T2WI scans showing brain lesions in the indicated groups of NMOSD mice. Red lines outline lesion areas. Scale bar: 2 mm. D Bar graph showing lesion volume in the indicated groups of NMOSD mice; n = 6 per group. The data are presented as the mean ± SEM. **p < 0.01

Article Snippet: An anti-CD22 monoclonal antibody (clone ID: CY34.1; BioXcell, West Lebanon, NH) was given to NMOSD mice via intrastriatal injection at a dose of 100 μg/mouse to deplete CD22-expressing cells [24].

Techniques:

Journal: Journal of neuroinflammation

Article Title: CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

doi: 10.1186/s12974-024-03305-2

Figure Lengend Snippet: Fig. 6 Gr-1+ myeloid cells contribute to exacerbating NMOSD pathology in mice receiving anti-CD22 mAb. A Flow chart depicting the drug administra tion and experimental procedures. Mice received anti-Gr-1 mAb before and one day after NMOSD induction. B Assessment of Gr-1+ myeloid cells in mice receiving anti-Gr-1 mAb or IgG control; n = 6 per group. C T2WI scans showing brain lesions in the indicated groups of NMOSD mice. Red lines mark the lesion areas. D Bar graph depicting lesion volume in the indicated groups of NMOSD mice; n = 6 per group. The data are presented as the mean ± SEM. **p < 0.01

Article Snippet: An anti-CD22 monoclonal antibody (clone ID: CY34.1; BioXcell, West Lebanon, NH) was given to NMOSD mice via intrastriatal injection at a dose of 100 μg/mouse to deplete CD22-expressing cells [24].

Techniques: Control

Journal: Journal of neuroinflammation

Article Title: CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

doi: 10.1186/s12974-024-03305-2

Figure Lengend Snippet: Fig. 7 CD22 blockade exacerbated NMOSD pathology in mice receiving anti-CD20 mAb. A Flow chart depicting the experimental procedures. The mice received anti-CD20 mAb three days prior to NMOSD induction. B Assessment of B cells in mice receiving anti-CD20 mAb; n = 6 per group. C T2WI scans showing brain lesions in the indicated groups of NMOSD mice. Red lines mark the lesion areas. D Bar graph showing lesion volume in the indicated groups of NMOSD mice; n = 6 per group. The data are presented as the mean ± SEM. **p < 0.01

Article Snippet: An anti-CD22 monoclonal antibody (clone ID: CY34.1; BioXcell, West Lebanon, NH) was given to NMOSD mice via intrastriatal injection at a dose of 100 μg/mouse to deplete CD22-expressing cells [24].

Techniques:

Journal: Journal of neuroinflammation

Article Title: CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

doi: 10.1186/s12974-024-03305-2

Figure Lengend Snippet: Fig. 8 The detrimental effects of CD22 blockade on NMOSD pathology involve SYK-GSK3β signaling. A Flow chart depicting the experimental pro cedures. The mice received R406 starting from the onset of modeling until they were sacrificed. B, C Assessment of the phosphorylation levels of SYK and GSK3β in the indicated groups of NMOSD mice; n = 4 per group. D T2WI scans showing brain lesions in the indicated groups of NMOSD mice. Bar graph showing lesion volume in the indicated groups of NMOSD mice. Red lines mark the lesion areas; n = 6 per group. The data are presented as the mean ± SEM. *p < 0.05

Article Snippet: An anti-CD22 monoclonal antibody (clone ID: CY34.1; BioXcell, West Lebanon, NH) was given to NMOSD mice via intrastriatal injection at a dose of 100 μg/mouse to deplete CD22-expressing cells [24].

Techniques: Phospho-proteomics